The clinical study of the safety and efficacy of denosumab for glucocorticoid-induced osteoporosis
Not Applicable
- Conditions
- Glucocorticoid-induced osteoporosis
- Registration Number
- JPRN-UMIN000015180
- Lead Sponsor
- Osaka Medical College
- Brief Summary
Denosumab significantly increased the mean BMD of the lumbar spine and bilateral hip (5.8%, and 1.3%, respectively).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 56
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with hypocalcemia
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The change of bone mineral density after 6 months, 12 months, 18 months,and 24 months
- Secondary Outcome Measures
Name Time Method The change of bone metabolism marker (BAP and TRACP-5b) after 3 months, 6 months, 12 months, 18 months,and 24 months